Refine
Has Fulltext
- yes (7)
Is part of the Bibliography
- yes (7)
Document Type
- Journal article (6)
- Doctoral Thesis (1)
Keywords
- PD-1 (3)
- BRAF (2)
- CTLA-4 (2)
- immune checkpoint blockade (2)
- treatment resistance (2)
- uveal melanoma (2)
- 1,2-Azaborinine (1)
- 1,2-azaborinines (1)
- Aromatische Verbindungen (1)
- Bisborole (1)
Introduction:
Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin’s lymphoma in a real-life clinical setting.
Methods:
Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators.
Results:
A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician’s visual analogue scale; mean improvement from baseline of 12.1 mm)
Im Rahmen dieser Arbeit konnte das Portfolio an literaturbekannten, freien Bisborolen beträchtlich erweitert werden. Die Reihe der Oligothiophen-verbrückten Borole konnte um die Vertreter der Ter- bzw. Quaterthiophene erweitert werden. Weiterhin wurden Lewisbasenaddukte mit IMes, CAAC und DMAP dargestellt und zur röntgenspektrographischen Charakterisierung herangezogen.
Durch den Vergleich der spektroskopischen Daten mit den bereits literaturbekannten Vertretern wurde eine schrittweise Entwicklung der Absorptionsmaxima in Abhängigkeit der Anzahl der Thienyleinheiten detektiert. Daraus konnte sowohl auf eine Verkleinerung der HOMO-LUMO-Abstände mit zunehmender Kettenlänge, als auch die Entwicklung zu einem Grenzwert bei einer hypothetisch unendlichen Kettenlänge geschlossen werden, welcher sich bei ca. ca. 2,40 eV befindet.
Weiterhin wurden 9,9-Dimethylfluoren und Biphenyl erfolgreich zu Bisborolen umgesetzt. Beide Systeme sind aufgrund ihrer strukturellen Gemeinsamkeiten sowie ihrer Vergleichbarkeit mit literaturbekannten Bis(borolyl)benzol - Verbindungen von besonderem Interesse. Zudem konnte ein Vergleich der spektroskopischen Daten aller literaturbekannten und im Rahmen dieser Arbeit dargestellten Bisborole bewerkstelligt werden.
Es wurde somit gezeigt, dass heteroaromatisch-verbrückte Bisborole eine größere energetische HOMO-LUMO-Lücke aufzeigen, als aromatisch-verbrückte Systeme. Zudem spielt die Position der Borolylgruppen und der damit verbundene Grad an pi-Interaktionen eine wichtige Rolle. Die beiden im Rahmen dieser Arbeit dargestellten Systeme 1,1'-(9,9-Dimethylfluoren-2,7-diyl)bis-(2,3,4,5-tetraphenylborol) und 4,4'-Bis(2,3,4,5-tetraphenylborol-1-yl)-1,1'-biphenyl reihen sich energetisch zwischen dem 1,3- bzw. 1,4-Bis(2,3,4,5-tetraphenylborol-1-yl)benzol ein. Insbesondere der Vergleich zwischen 1,4-Bis(2,3,4,5-tetraphenylborol-1-yl)benzol und 4,4'-Bis(2,3,4,5-tetraphenylborol-1-yl)-1,1'-biphenyl offenbart keine signifikante Energiedifferenz zwischen einer Phenyl- und einer Biphenylbrücke, was ein Indiz dafür darstellt, dass die Erweiterung des Spacers um eine zweite Phenyleinheit bei analoger 1,4-Verknüpfung nahezu keinen Einfluss auf die elektronischen Eigenschaften des Systems hat.
Auch die Überführung von 1,1'-(9,9-Dimethylfluoren-2,7-diyl)bis-(2,3,4,5-tetraphenylborol) und 4,4'-Bis(2,3,4,5-tetraphenylborol-1-yl)-1,1'-biphenyl in die entsprechenden 1,2-Azaborinine wurde unter Verwendung von Trimethylsilylazid bewerkstelligt.
Neben der Darstellung und Untersuchung neuer Bisborole wurde 9-(Thiophen-2-yl)carbazol erfolgreich für den Aufbau borhaltiger Donor-Akzeptor-Systeme eingesetzt. Es konnten im Zuge dessen ein Borol und dessen IMes-Addukt, ein 1,2-Azaborinin sowie ein Dimesitylboryl-substituiertes Derivat dargestellt und auf ihre optischen und elektronischen Eigenschaften hin untersucht werden. Dabei stand insbesondere die elektrochemische Quantifizierung der Elektronenakzeptorstärke des Borols im Vergleich zum Dimesitylboran im Fokus. Es wurde ein signifikanter Unterschied des Borols (Epc = -1.60 V, CH2Cl2) im Vergleich zum Dimesitylboran (E1/2 = -2.39 V, THF) detektiert, woraus eine deutlich höhere Akzeptorstärke des Borols abgeleitet werden kann.
Zusätzlich wurden spektroskopische und photophysikalische Untersuchungen in Abhängigkeit der jeweiligen Verbindung durchgeführt. Durch den Vergleich des energetisch niedrigsten Absorptionsmaximas des Borols mit bereits literaturbekannten, thienylsubstituierten Borolen konnte ein signifikanter Donoreinfluss der Carbazoleinheit bestätigt werden.
Background: Since there is no standardized and effective treatment for advanced uveal melanoma (UM), the prognosis is dismal once metastases develop. Due to the availability of immune checkpoint blockade (ICB) in the real-world setting, the prognosis of metastatic UM has improved. However, it is unclear how the presence of hepatic and extrahepatic metastasis impacts the response and survival after ICB. Methods: A total of 178 patients with metastatic UM treated with ICB were included in this analysis. Patients were recruited from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of hepatic metastasis, two cohorts were compared: patients with liver metastasis only (cohort A, n = 55) versus those with both liver and extra-hepatic metastasis (cohort B, n = 123). Data were analyzed in both cohorts for response to treatment, progression-free survival (PFS), and overall survival (OS). The survival and progression probabilities were calculated with the Kaplan–Meier method. Log-rank tests, χ\(^2\) tests, and t-tests were performed to detect significant differences between both cohorts. Results: The median OS of the overall population was 16 months (95% CI 13.4–23.7) and the median PFS, 2.8 months (95% CI 2.5–3.0). The median OS was longer in cohort B than in cohort A (18.2 vs. 6.1 months; p = 0.071). The best objective response rate to dual ICB was 13.8% and to anti-PD-1 monotherapy 8.9% in the entire population. Patients with liver metastases only had a lower response to dual ICB, yet without significance (cohort A 8.7% vs. cohort B 16.7%; p = 0.45). Adverse events (AE) occurred in 41.6%. Severe AE were observed in 26.3% and evenly distributed between both cohorts. Conclusion: The survival of this large cohort of patients with advanced UM was more favorable than reported in previous benchmark studies. Patients with both hepatic and extrahepatic metastasis showed more favorable survival and higher response to dual ICB than those with hepatic metastasis only.
Adjuvant treatment of melanoma patients with immune-checkpoint inhibition (ICI) and targeted therapy (TT) significantly improved recurrence-free survival. This study investigates the real-world situation of 904 patients from 13 German skin cancer centers with an indication for adjuvant treatment since the approval of adjuvant ICI and TT. From adjusted log-binomial regression models, we estimated relative risks for associations between various influence factors and treatment decisions (adjuvant therapy yes/no, TT vs. ICI in BRAF mutant patients). Of these patients, 76.9% (95% CI 74–80) opted for a systemic adjuvant treatment. The probability of starting an adjuvant treatment was 26% lower in patients >65 years (RR 0.74, 95% CI 68–80). The most common reasons against adjuvant treatment given by patients were age (29.4%, 95% CI 24–38), and fear of adverse events (21.1%, 95% CI 16–28) and impaired quality of life (11.9%, 95% CI 7–16). Of all BRAF-mutated patients who opted for adjuvant treatment, 52.9% (95% CI 47–59) decided for ICI. Treatment decision for TT or ICI was barely associated with age, gender and tumor stage, but with comorbidities and affiliated center. Shortly after their approval, adjuvant treatments have been well accepted by physicians and patients. Age plays a decisive role in the decision for adjuvant treatment, while pre-existing autoimmune disease and regional differences influence the choice between TT or ICI.
We identified the dsRNA binding protein RbdB as an essential component in miRNA processing in Dictyostelium discoideum. RbdB is a nuclear protein that accumulates, together with Dicer B, in nucleolar foci reminiscent of plant dicing bodies. Disruption of rbdB results in loss of miRNAs and accumulation of primary miRNAs. The phenotype can be rescued by ectopic expression of RbdB thus allowing for a detailed analysis of domain function. The lack of cytoplasmic dsRBD proteins involved in miRNA processing, suggests that both processing steps take place in the nucleus thus resembling the plant pathway. However, we also find features e.g. in the domain structure of Dicer which suggest similarities to animals. Reduction of miRNAs in the rbdB- strain and their increase in the Argonaute A knock out allowed the definition of new miRNAs one of which appears to belong to a new non-canonical class.
Re-induction with immune checkpoint blockade (ICB) needs to be considered in many patients with uveal melanoma (UM) due to limited systemic treatment options. Here, we provide hitherto the first analysis of ICB re-induction in UM. A total of 177 patients with metastatic UM treated with ICB were included from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of ICB re-induction, two cohorts were compared: patients who received at least one ICB re-induction (cohort A, n = 52) versus those who received only one treatment line of ICB (cohort B, n = 125). In cohort A, a transient benefit of overall survival (OS) was observed at 6 and 12 months after the treatment start of ICB. There was no significant difference in OS between both groups (p = 0.1) with a median OS of 16.2 months (cohort A, 95% CI: 11.1–23.8) versus 9.4 months (cohort B, 95% CI: 6.1–14.9). Patients receiving re-induction of ICB (cohort A) had similar response rates compared to those receiving ICB once. Re-induction of ICB may yield a clinical benefit for a small subgroup of patients even after resistance or development of toxicities.
Background:
Concomitant radiation with BRAF inhibitor (BRAFi) therapy may increase radiation-induced side effects but also potentially improve tumour control in melanoma patients.
Methods:
A total of 155 patients with BRAF-mutated melanoma from 17 European skin cancer centres were retrospectively analysed. Out of these, 87 patients received concomitant radiotherapy and BRAFi (59 vemurafenib, 28 dabrafenib), while in 68 patients BRAFi therapy was interrupted during radiation (51 vemurafenib, 17 dabrafenib). Overall survival was calculated from the first radiation (OSRT) and from start of BRAFi therapy (OSBRAFi).
Results:
The median duration of BRAFi treatment interruption prior to radiotherapy was 4 days and lasted for 17 days. Median OSRT and OSBRAFi in the entire cohort were 9.8 and 12.6 months in the interrupted group and 7.3 and 11.5 months in the concomitant group (P=0.075/P=0.217), respectively. Interrupted vemurafenib treatment with a median OSRT and OSBRAFi of 10.1 and 13.1 months, respectively, was superior to concomitant vemurafenib treatment with a median OSRT and OSBRAFi of 6.6 and 10.9 months (P=0.004/P=0.067). Interrupted dabrafenib treatment with a median OSRT and OSBRAFi of 7.7 and 9.8 months, respectively, did not differ from concomitant dabrafenib treatment with a median OSRT and OSBRAFi of 9.9 and 11.6 months (P=0.132/P=0.404). Median local control of the irradiated area did not differ in the interrupted and concomitant BRAFi treatment groups (P=0.619). Skin toxicity of grade ≥2 (CTCAE) was significantly increased in patients with concomitant vemurafenib compared to the group with treatment interruption (P=0.002).
Conclusions:
Interruption of vemurafenib treatment during radiation was associated with better survival and less toxicity compared to concomitant treatment. Due to lower number of patients, the relevance of treatment interruption in dabrafenib treated patients should be further investigated. The results of this analysis indicate that treatment with the BRAFi vemurafenib should be interrupted during radiotherapy. Prospective studies are desperately needed.